Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Rises By 27.1%

Atyr PHARMA INC (NASDAQ:ATYR) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 2,110,000 shares, an increase of 27.1% from the October 31st total of 1,660,000 shares. Based on an average daily volume of 858,600 shares, the days-to-cover ratio is presently 2.5 days. Currently, 2.6% of the shares of the company are sold short.

Atyr PHARMA Trading Up 2.6 %

Shares of Atyr PHARMA stock opened at $3.53 on Friday. The company’s 50-day simple moving average is $2.75. Atyr PHARMA has a twelve month low of $1.14 and a twelve month high of $3.80. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). On average, equities analysts forecast that Atyr PHARMA will post -0.89 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Wells Fargo & Company assumed coverage on shares of Atyr PHARMA in a report on Friday, October 4th. They set an “overweight” rating and a $17.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $35.00 price target on shares of Atyr PHARMA in a research note on Tuesday, October 29th. Jefferies Financial Group started coverage on Atyr PHARMA in a research report on Thursday, September 5th. They issued a “buy” rating and a $9.00 price objective for the company. Finally, Royal Bank of Canada restated an “outperform” rating and set a $16.00 price objective on shares of Atyr PHARMA in a research report on Wednesday, August 14th.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.